AQR Capital Management LLC trimmed its stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 25.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,460 shares of the biopharmaceutical company’s stock after selling 5,638 shares during the quarter. AQR Capital Management LLC’s holdings in Fate Therapeutics were worth $54,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in FATE. Squarepoint Ops LLC acquired a new stake in shares of Fate Therapeutics during the second quarter worth $422,000. Integral Health Asset Management LLC raised its holdings in shares of Fate Therapeutics by 325.0% during the second quarter. Integral Health Asset Management LLC now owns 850,000 shares of the biopharmaceutical company’s stock worth $2,788,000 after purchasing an additional 650,000 shares during the period. DRW Securities LLC acquired a new stake in shares of Fate Therapeutics during the second quarter worth $71,000. XTX Topco Ltd raised its holdings in shares of Fate Therapeutics by 95.0% during the second quarter. XTX Topco Ltd now owns 33,898 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 16,510 shares during the period. Finally, Hsbc Holdings PLC raised its holdings in shares of Fate Therapeutics by 34.3% during the second quarter. Hsbc Holdings PLC now owns 88,514 shares of the biopharmaceutical company’s stock worth $283,000 after purchasing an additional 22,583 shares during the period. 97.54% of the stock is currently owned by institutional investors.
Fate Therapeutics Stock Up 0.3 %
Shares of FATE opened at $3.23 on Friday. The firm has a 50-day moving average price of $3.50 and a 200 day moving average price of $4.00. The firm has a market capitalization of $367.68 million, a PE ratio of -1.68 and a beta of 1.83. Fate Therapeutics, Inc. has a 52-week low of $1.63 and a 52-week high of $8.83.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on FATE. Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a report on Wednesday, August 14th. HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price objective on shares of Fate Therapeutics in a report on Thursday, August 22nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Fate Therapeutics presently has an average rating of “Hold” and an average target price of $6.90.
Check Out Our Latest Report on Fate Therapeutics
About Fate Therapeutics
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Featured Stories
- Five stocks we like better than Fate Therapeutics
- What to Know About Investing in Penny Stocks
- Survey Reveals: America’s Most Coveted Businesses in 2024
- What is a Bond Market Holiday? How to Invest and Trade
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Want to see what other hedge funds are holding FATE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report).
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.